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  QUANTITATIVE ESTIMATION OF TRIMAZOLIN 
HYDROCHLORIDE IN PHARMACEUTICAL 
PREPARATION BY RP-HPLC METHOD 
A sensitive and selective RP–HPLC method was developed and validated for the quan-
titative determination of trimazolin hydrochloride in nasal drops formulations. The 
mobile phase composition was water–acetonitrile (50:50, v/v) and the UV detection 
was carried out at 270 nm. Linearity range in the concentration range of 10 to 110 μg 
cm
-3. The method was tested and validated for various parameters according to ICH 
guidelines. The detection and quantization limits were found to be 1.45 and 4.8 μg cm
-3, 
respectively. The results demonstrated that the procedure for estimation of trimazolin 
hydrochloride in nasal drops formulations was accurate, precise and reproducible. 
 
 
Nasal stuffiness or congestion occurs as a result of 
swelling of the nasal membranes. Histamine opens the 
blood vessels and encourages the fluid leakage from 
them, thereby causing the tissues to become “conges-
ted”. This reaction reduces the space inside the nose 
through which we breathe and results in the typical 
“blocked” or stuffy nose. While antihistamines can con-
trol many symptoms of allergic rhinitis, they are not 
very helpful for treating nasal congestion once it has 
already occurred [1]. At this point, decongestants can be 
a very useful addition. Decongestants act on a receptor 
on the blood vessels. The blood vessels thereby shrink, 
which in turn reduces the blood flow to the area and 
lessens the leakage of the fluid into the tissues. The 
result is a nasal passage that feels more “open”. It is 
important to remember that decongestants do not help 
with an itchy, sneezing, and runny nose. 
Nasal preparations are liquid, semi-solid or solid 
preparations intended for administration to the nasal ca-
vities obtain a systemic or local effect. Nasal prepara-
tions are as far as possible non-irritating and do not ad-
versely affect the functions of the nasal mucosa and its 
cilia. Aqueous nasal preparations are usually isotonic 
and may contain excipients, for example, to adjust the 
viscosity of the preparation, to adjust or stabilize the 
pH, to increase the solubility of the active substance, or 
to stabilize the preparation [2]. Unless otherwise justi-
fied and authorized, aqueous nasal preparations supplied 
in multidose containers comprise a suitable antimicro-
bial preservative in appropriate concentration, except 
where the preparation itself has adequate antimicrobial 
properties. 
In practice, a great number of this type of prepara-
tions, which most often contain ephedrine and phenyl-
eprine as adrenergic vasoconstrictors, are commercially 
                                                 
  Corresponding author: I. M. Savić, Department of Pharmaceutics, 
Faculty of Technology, Bulevar oslobodjenja 124, 16000 Leskovac, 
Serbia. 
E-mail: ici86@info-net.rs 
Paper received: 5 February, 2009. 
Paper accepted: 24 March, 2009. 
present today [3]. Various methods have been reported 
in literature for the analysis of phenylephrine hydro-
chloride including spectrophotometry [4–8], spectro-
photometry with chromogenic reagent [9], fluorometry 
[10], chromatography [11,12]. High-performance liquid 
chromatography [13–16], micellar liquid chromatogra-
phy [17], micellar electrokinetic chromatography [18], 
capillary zone electrophoresis [19,20], spectro-fluori-
metric and derivative spectrophotometric methods [21], 
are also reported for determination of phenylephrine 
hydrochloride. 
As pharmaceutically active substances, ephedrine 
and phenylephrine can act alone or can be combined 
with other substances of the similar effect, thus increas-
ing the preparation efficiency. The object of this investi-
gation is a decongestive preparation of Adrianol drops 
(Zdravlje-Actavis, Leskovac, Serbia). Besides phenyl-
ephrine, adrianol contains trimazolin hydrochloride as an 
adrenergic vasoconstrictor. The efficiency of the prepa-
ration is increased by the use of trimazolin hydrochloride. 
Trimazolin hydrocloride ((2-(2,4,6-trimethylben-
zyl)-imidazoline hydrochloride) is an alpha-adrenergic 
(sympathomimetic) (Fig. 1) [22]. 
 
Figure 1. Chemical structure of trimazolin hydrochlorid. 
Slika 1. Hemijska struktura trimazolin-hidrohlorida. 
It is a white, crystalline, almost odorless, bitter sub-
stance, freely soluble in water, slightly soluble in etha-
nol, insoluble in ether and acetone. The melting point is 
in the range of 279–281 C. A 10% aqueous solution 
has a pH of about 5.5–6.5 [23]. 
Various methods have been reported in literature 
for the analysis of phenylephrine hydrochloride. How-
ever, in domestic and foreign pharmacopoeias, as well 
as in scientific literature, there are no data on trimazolin 
and the methods of its investigation [24–27]. The patent I. M. SAVIĆ et al.: QUANTITATIVE ESTIMATION OF TRIMAZOLIN...  Hem. ind. 63 (2) 87–93 (2009) 
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literature has data on only the trimazolin and trimazolin 
hydrochloride synthesis procedure, without physico–
chemical, spectroscopic characterization and other in-
vestigation methods [25]. 
For the routine analysis, a simple and rapid HPLC 
method is suggested in the paper. A literature survey of 
literature has not revealed any simple validated RP-HPLC 
method for estimating trimazolin hydrochloride in nasal 
drops formulations. The development of simple and ac-
curate RP-HPLC methods can provide a very useful al-
ternative for the routine analysis of nasal formulations 
and dissolution samples. The object of the present study 
was to develop simple, precise, accurate and validated, 
economic analytical methods for the estimation of tri-
mazolin hydrochloride in a pure form and in pharma-
ceutical nasal formulations. In order to be useful for the 
drug testing, the proposed method should be validated 
according to the ICH regulations [29–30], and Ph. Yug. 
V  [24]. Statistical tests were performed on validation 
data [31–32]. 
EXPERIMENTAL 
Apparatus 
The method development was performed with an 
Agilent 1100-Series HPLC system consisting of an Agi-
lent 1100-Series variable wavelength UV detector and 
an Agilent 1100-Series autosampler using a 50 μL sam-
ple loop (Faculty of Technology, Leskovac). The sys-
tem was controlled and data analyses were performed 
with the Agilent HPLC Data Analysis software. The as-
says (repeatability) were performed with another LC 
system consisting of a Agilent 1100-Series binary pump 
and Agilent 1100-Series DAD detector (Zdravlje-Acta-
vis, Leskovac). The detector was set at 270 nm and the 
peak areas were integrated automatically by the compu-
ter using the Agilent HPLC Data Analysis software pro-
gram. The separation was carried out at ambient tempe-
rature using a ZORBAX Eclipse XDB-C18 column, 
(4.6 mm250 mm, 5 μm). All the calculations concern-
ing the quantitative analysis were performed with the 
external standardization by measuring the peak areas. 
Chromatographic conditions 
RP-HPLC analysis was performed by isocratic elu-
tion with a flow rat of 0.8 cm
3 min
-1. The mobile phase 
composition was water–acetonitrile (50:50 v/v). All sol-
vents were filtered through a 0.45 μm millipore filter. 
Volumes of 50 μL of the solutions and samples prepared 
were injected into the column. Quantification was ef-
fected by measuring at 270 nm as established from the 
two-dimensional chromatogram. Throughout the study, 
the suitability of the chromatographic system was moni-
tored the efficiency column and peak asymmetry. 
Chemicals 
The standard of trimazolin hydrochloride (99.96%) 
and the standard of phenylephrine hydrochloride (99.98%) 
were kindly donated by the Pharmaceutical and Chemi-
cal Industry Zdravlje-Actavis (Leskovac, Serbia) and 
used without further purification. 
Pharmaceutical preparation 
Commercial pharmaceutical preparations Adrianol-T 
nasal drops (for children) and Adrianol nasal drops (for 
adults), containing trimazolin hydrochloride, were kind-
ly donated by Zdravlje-Actavis. Adrianol-T nasal drops 
were labeled to contain 0.5 mg cm
-3 of trimazolin hyd-
rochloride and 0.5 mg cm
-3 of phenylephrine hydrochlo-
ride. Adrianol nasal drops were labeled to contain 1.5 
mg cm
-3 of trimazolin hydrochloride and 1 mg cm
-3 of 
phenylephrine hydrochloride. Adrianol formulations con-
tain excipients like disodium hydrophosphate dihydrate, 
citric acid monohydrate, methyl cellulose M.H.B. 10000, 
glycerol, phenyl–mercury(II) borate, ammonium hydro-
xide, ethanol 96% and pure water. All other chemicals 
and reagents used were of analytical grade (Merck 
Chem. Ind.). 
Stock and standard solution 
One stock solution of 0.5 mg cm
−3 trimazolin hyd-
rochloride was prepared by dissolving 25 mg of trima-
zolin hydrochloride in a 50 cm
3 mobile phase. The stock 
solution of 0.5 mg cm
−3 phenylephrine hydrochloride 
was prepared by dissolving 25 mg of phenylephrine hy-
drochloride in a 50 cm
3 mobile phase. 
Procedure for calibration curve 
For preparing different concentrations, aliquots of 
the stock solution were transferred into a series of 10 
cm
3 standard volumetric flasks and the volumes were 
made with the respective media. Ten different concen-
trations were prepared in the range of 10–110 g cm
−3 
of trimazolin hydrochloride in mobile phase for a stan-
dard curve. In a similar way, five different concentra-
tions were prepared in the range of 100–500 g cm
−3 of 
trimazolin hydrochloride considering the declaration va-
lue. Triplicate 50 μL injections were made for each so-
lution. The final concentrations of trimazolin hydrochlo-
ride in the samples were calculated by comparing the 
sample and standard peak obtained with the average of 
three injections of standard solutions. 
Sample preparation 
Aliquots (1 cm
3) of nasal drop preparations (Adri-
anol-T or Adrianol) equivalent to 0.5 mg and 1.5 mg of 
trimazolin hydrochloride, respectively, were taken and 
suitably diluted with the mobile phase in order to get a 
50 g cm
−3 concentration and the samples were injected 
into the chromatograph. I. M. SAVIĆ et al.: QUANTITATIVE ESTIMATION OF TRIMAZOLIN...  Hem. ind. 63 (2) 87–93 (2009) 
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Validation 
For specificity and selectivity of method, trimazo-
lin hydrochloride solutions (50 g cm
−3) were prepared 
in the mobile phase along with and without common 
excipients, separately. All the solutions were injected 
into the XDB-C18 RP-HPLC column. In this assay, it 
was tested by running solutions containing the placebo 
of the specialties in the same quantities and in the con-
ditions in which the samples to show that there is no 
peak in the retention times corresponding to the analy-
tes. Paired t-test at 95% level of significance was per-
formed to compare the area of peak (n = 10) (Table 1). 
Table 1. Statistical data of the regression equations and 
validation parameters for trimazolin hydrocloride (n = 10) 
Tabela 1. Statistički podaci regresione jednačine i potvrdnih 
parametara za trimazolin-hidrohlorid (n = 10) 
Parameter Value 
Slope (SE)
a 2842.4163  (165.43)
Intercept (SE)
a 87.8169  (10.61) 
Regression coefficient (r) 0.9884 
Specificity and selectivity, t
b  1.94 
Linearity (μg cm
-3) 10–110 
Limit of detection (LOD, μg cm
-3) 4.8 
Limit of quantification (LOQ, μg cm
-3) 12.3 
aStandard error of mean; 
btheoretical values at 95% confidence limits
t = 2.225 
The linearity study verifies that the sample solu-
tions are in a concentration range where analyte res-
ponse is linearly proportional to the concentration. To 
establish linearity of the proposed methods, eleven sepa-
rate series of trimazolin hydrochloride solutions (10– 
–110 g cm
−3 in the mobile phase) were prepared from 
the stock solutions and analyzed. Least square regres-
sion analysis was done for the data obtained. 
The accuracy of the method is the closeness of the 
measured value to the true value for the sample. To de-
termine the accuracy of the proposed method, different 
levels of drug concentrations – lower concentration (LC, 
80%), intermediate concentration (IC, 100%) and higher 
concentration (HC, 120%) were prepared from indepen-
dent stock solutions and analyzed (n = 10). Accuracy 
was assessed as the percentage relative error and mean% 
recovery (Table 2). To provide an additional support to 
the accuracy of the developed assay method, the stan-
dard addition method was employed, which involved 
the addition of different concentrations of pure drug (10, 
20 and 30 μg cm
-3) to a known preanalyzed formulation 
sample and the total concentration was determined using 
the proposed methods (n = 10 ). The recovery of the 
added pure drug was calculated as %Recovery = ((ct – 
– cs)/ca)100, where ct is the total drug concentration 
measured after standard addition; cs, drug concentration 
in the formulation sample; ca, drug concentration added 
to formulation (Table 3). 
Table 2. Accuracy and the precision data for the developed 
method (n = 10) 
Tabela 2. Tačnosti i preciznost podataka za korišćeni metod (n 
= 10) 
Predicted concentration 
μg cm
-3  Level 
Mean ± SD % RSD 
Mean recovery ± SD 
% 
LC (40 μg cm
-3) 40.23 ± 0.326  0.812  100.57 ± 0.326 
IC (50 μg cm
-3) 50.21 ± 0.337  0.672  100.42 ± 0.337 
HC (60 μg cm
-3) 59.92 ± 0.321  0.533  99.87 ± 0.321 
Table 3. Standard addition of trimazolin hydrocloride for 
accuracy (n = 10) 
Tabela 3. Standardni dodatak trimazolin hidrohlorida u cilju 
tačnosti (n = 10, c = 50 μg cm
-3) 
Pure drug added 
μg cm
-3 
Total drug found ± SD 
μg cm
-3 
Recovery±RSD
% 
0  50.21 ± 0.34  100.42 ± 0.67 
10  59.92 ± 0.32  99.87 ± 0.58 
20  70.35 ± 0.45  100.50 ± 0.64 
30  79.87 ± 0.42  99.84 ± 0.53 
The repeatability was determined by using differ-
rent levels of drug concentrations (the same concentra-
tion levels taken in the accuracy study), prepared from 
independent stock solutions and analyzed (n = 10) (Tab-
le 2). Inter-day, intra-day and inter-instrument variation 
were studied to determine the intermediate precision of 
the proposed analytical methods. Different levels of drug 
concentrations in triplicates were prepared three differ-
rent times in a day and studied for intra-day variation. 
The same procedure was followed for three different 
days in order to study the inter-day variation (n = 10). 
One set of different levels of the concentrations was re-
analyzed using another HPLC Agilent 1100-Series sys-
tem, by proposed methods to study inter-instrument va-
riation (n = 10). The relative standard deviation (%RSD) 
of the predicted concentrations from the regression equa-
tion was taken as precision (Table 4). The precision stu-
dies were also carried out by using the real samples of 
trimazolin nasal drops preparation (0.5 mg cm
-3) in a si-
milar way to a standard solution to prove the usefulness 
of method. 
The limit of detection  (LOD) was calculated by 
comparison of the three-fold variation of signal to noise 
ratio (3 S/N) obtained from analysis of the standards. 
The limit of quantification (LOQ) was defined as 
the lowest measured quantity above which the analyte 
can be quantified at a given statistical level of (10 S/N). 
LOD and LOQ were experimentally verified by ten in-
jections of trimazolin hydrochloride at the LOD and 
LOQ concentrations (n = 10) (Table 1). I. M. SAVIĆ et al.: QUANTITATIVE ESTIMATION OF TRIMAZOLIN...  Hem. ind. 63 (2) 87–93 (2009) 
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To determine the robustness of the developed me-
thod, experimental conditions were purposely altered. 
The flow rate of the mobile phase was 0.8 cm
3 min
-1. To 
study the effect of flow rate on the resolution, it was 
changed by 0.2 units from 0.6 to 1 cm
3 min
-1, while the 
other mobile phase components were held constant as 
per method. The effect of column temperature on reso-
lution was studied at 20 and 30 C instead of 25 C, 
while the other mobile phase components were held 
constant as per method. 
Comparative method 
The employed procedure for the comparative me-
thod (UV spectrophotometry) is described in the other 
paper [33]. 
RESULTS AND DISCUSSION 
HPLC method optimization 
A RP-HPLC method was developed for trimazolin 
hydrochloride and it can be conveniently employed for 
routine quality control in pharmaceutical dosage forms. 
The chromatographic conditions were optimized in or-
der to provide a good performance of the assay. During 
the optimization of the method different stationary pha-
ses like C18, C8 and cyano, different mobile phases and 
using organic modifiers like methanol in the mobile 
phase. The chromatographic separation was achieved on 
a ZORBAX Eclipse XDB-C18 column (4.6 mm250 
mm), with a particle size of 5 μm. Satisfactory separa-
tion of used standards was obtained with a mobile phase 
consisting of water–acetonitrile (50:50 v/v). If methanol 
was used instead of acetonitrile, the separation of trima-
zolin hydrochloride and phenyleprine was also with un-
satisfactory resolution in nasal formulations. The maxi-
mum absorption of trimazolin hydrochloride was detec-
ted at 270 nm and this wavelength was chosen for the 
analysis. The retention times for the standard solution of 
trimazolin hydrochloride (0.5 mg cm
-3) and trimazolin 
hydrochloride in Adrianol-T nasal drops preparation were 
observed to be 4.5 min and 4.570 min, respectively (Fig. 
2a and 2d). 
The retention time for the standard solution of phe-
nylephrine hydrochloride (0.5 mg cm
-3) and phenyle-
phrine hydrochloride in Adrianol-T nasal drops prepa-
ration were observed to be 2.255 and 2.321 min, res-
pectively (Fig. 2a and 2d). Total time of the analysis 
was less than 10 min. 
The chromatographic parameters, such as efficiency 
column and peak asymmetry were reconsidered for the 
trimazolin hydrochloride standard. According to the ob-
tained value Number of Theoretical Plato (N = 324), the 
conclusion is that the efficiency column is satisfactory 
(HETP = 0.771). The 0.41 asymmetry peak value indi-
cates that the peak is not ideally symmetric, that is, it is 
not a Gauss peak. Having in mind that Wab < Wbc, this 
means that there is a certain interaction between the sta-
tionary phase and the investigated component. A similar 
effect was noticed in the analysis of Adrianol prepara-
tion which explains the movement of the peak from 
4.500 to 4.570 min (Fig. 2d). 
 
Figure 2. The HPLC chromatograms at 270 nm of trimazolin 
hydrochloride standard (A), phenylephrine standard (B), 
placebo (C) and Adrianol-T nasal drops preparation (D). 
Slika 2. HPLC hromatogrami pri 270 nm za trimazolin 
hidrohlorid standard (A), fenilefrin standard (B), placebo (C) 
i adrianol-T (D). 
Calibration curve 
Excellent linearity was obtained between the peak 
areas and the concentrations. The linear regression equa-
tion obtained with a regression coefficient, r of 0.9884 
and standard deviation, SD of 18.0621 was: A270 =   
= (2842.4163×c (mg cm
−3) + 87.8169). Linearity range 
was not obeyed in the range of 100–500 g cm
−3, con-
sidering a declaration value of Adrianol-T preparation, 
but linearity range was obeyed in the concentration ran-
ge of 10–110 gcm
−3. I. M. SAVIĆ et al.: QUANTITATIVE ESTIMATION OF TRIMAZOLIN...  Hem. ind. 63 (2) 87–93 (2009) 
 
       91 
Validation 
The chromatogram of trimazolin hydrochloride 
was not changed in the presence of common excipients 
used in the formulation of nasal drops. The chromato-
gram of the pure drug sample was matched with the 
formulation samples in mobile phase (Fig. 2c). The cal-
culated t-values were found to be less than that of the 
tabulated  t-values (Table 1). Therefore, the proposed 
analytical method is specific and selective for the drug. 
The linearity range for trimazolin hydrochloride 
estimation was found to be 10–110 g cm
−3 (r = 0.9884) 
(Table 1). 
Goodness of the fit of the regression equations was 
supported by high regression coefficient values. 
The accuracy was determined in range from 20 to 
60 μg cm
-3(Table 2). 
The excellent mean %recovery values, close to 
100%, and their low standard deviation values (RSD < 
1.0) represent high accuracy of the analytical methods. 
The validity and reliability of the proposed methods was 
further assessed by recovery studies via standard addi-
tion method. The mean %recoveries (%RSD) for con-
centration of 50 μg cm
-3 showed in Table 3. 
These results revealed that any small change in the 
drug concentration in the solutions could be accurately 
determined by the proposed analytical methods. 
Precision was determined by studying the repea-
tability and the intermediate precision. Repeatability 
(%RSD) ranged from 40 to 60 g cm
-3, at all three levels 
of trimazolin hydrochloride concentrations (Table 4). 
Table 4. System precision study (n = 10) 
Tabela 4. Preciznost sistema (n = 10) 
Intra-day repeatability 
%RSD (n = 10)  c / μg cm
-3 
Day 1  Day 2  Day 3 
Intra-instrument 
repeatability 
%RSD (n = 10) 
40 39.65 
(0.812) 
39.94 
(0.672) 
40.48 
(0.512) 
38.96 (0.889) 
50 49.85 
(0.05) 
50.32 
(0.212) 
49.88 
(0.08) 
50.35 (1.408) 
60 60.55 
(0.183) 
60.51 
(0.842) 
60.15 
(0.083) 
60.34 (1.547) 
The repeatability results indicated the precision un-
der the same operating conditions over a short interval 
of time and the inter-assay precision. The intermediate 
precision expresses within-laboratory variations in dif-
ferent days and in different instruments. In the interme-
diate precision study, %RSD values were not more than 
2.0% in all the cases (Table 4). RSD values found for 
the proposed analytical method were well within the ac-
ceptable range indicating that the method had excellent 
repeatability and the intermediate precision. %RSD va-
lues for the precision studies with real samples of nasal 
drops were found to be less than 2. 
LOD and LOQ were found to be 1.45 and 4.8 
gcm
−3 for trimazolin hydrochloride (Table 1). 
Robustness 
In all the deliberately varied chromatographic con-
ditions (flow rate and column temperature) no signifi-
cant change in the assay value was observed. The sys-
tem suitability parameters like tailing and the RSD va-
lues were well within the limits. Tailing was 1.0 and 0.9 
and RSD was 0.8 and 0.6% for flow rate and column 
temperature variations, which confirms the robustness 
of the developed method. 
Applicability of the proposed method 
The imposed method was applied for the determi-
nation of trimazolin hydrochloride in pharmaceutical 
formulations using the direct calibration curve. As it can 
be seen in Table 5, the results obtained for this method 
are in accordance with the UV spectrophotometric me-
thod. The results of the imposed method were statistic-
cally compared with those of the UV spectrophotomet-
ric method using a point hypothesis test [34,35]. Table 5 
shows that the calculated F and t values at the 95% con-
fidence level are less than the theoretical ones, confirm-
ing no significant differences between the performance 
of the proposed and the UV spectrophotometric method. 
Estimation of formulations 
The assay value of trimazolin hydrochloride in pre-
parations ranged from 98.40 to 101.20% with standard 
deviation not more than 0.0091% (Table 6). Assay va-
lues of formulations were the same as mentioned in the 
label claim indicating that the interference of excipient 
matrix is insignificant in the estimation of trimazolin 
hydrochloride by the proposed analytical methods. The 
estimated drug content with low values of standard de-
viation established the precision of the proposed me-
thod. The calculated Student’s t-values did not exceed 
the tabulated values (Table 6). 
 
Table 5. Determination of trimazolin hydrochloride by the HPLC and the UV spectrophotometry 
Tabela 5. Određivanje trimazolin-hidrohlorida HPLC i UV spektrometrijom 
Pharmaceutical preparation 
Taken 
μgcm
−3 
Trimazolin hydrochloride found 
by HPLC
a (xSD, μgcm
−3) 
RSD
a
% 
Recovery
a
%  F
b  t
b 
UV spectrophotometry
xSD, μg cm
−3 
Trimazolin hydrochloride  50  50.210.34 0.67  100.42  1.36  1.03  49.750.29 
aData are based on the average obtained from five determinations; 
btheoretical F value (ν1 = 4, ν2 = 4) and t value (ν = 8) at the 95% confidence level 
are 6.39 and 2.31, respectively I. M. SAVIĆ et al.: QUANTITATIVE ESTIMATION OF TRIMAZOLIN...  Hem. ind. 63 (2) 87–93 (2009) 
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Table 6. Assay results for the determination of trimazolin 
hydrochloride in commercial nasal solution (Adrianol-T and 
Adrianol) 
Tabela 6. Rezultati određivanja trimazolin-hirohlorida u 
komercijalnim rastvorima adrianol-T I adrianol 
Sample (preparation)  Adrianol-T 
Total trimazolin hydrochloride 
found (±SD), mg cm
-3 
0.506 ± 0.0091 
Accuracy
a, %  1.20 
t
b  1.98 
Sample Adrianol 
Total trimazolin hydrochloride 
found (±SD), mg cm
-3 
0.494 ± 0.0086 
Accuracy
a, %  1.60 
t
b  2.09 
aAccuracy is givin in % relative error (100(predicted concentration–
–nominal concetration)/nominal concentration); 
btheoretical values at
95% confidence limits t = 2.225 
CONCLUSION 
The proposed RP-HPLC method is simple, sen-
sitive, rapid and specific and can be used for in a drug 
manufacturing quality control of trimazolin hydrochlo-
ride in nasal drops formulations. The method described 
in this study was suitable to determine concentrations in 
the range 0.01 to 0.11 mg cm
-3 for trimazolin hydrochlo-
ride, precisely and accurately. Limits of detection and 
quantization for trimazolin hydrochloride with lower 
concentration were 1.45 and 4.8 gcm
−3, respectively, 
values which are under the lowest expected concentra-
tions in the sample. The sample recovery from the for-
mulation was in good agreement with its respective la-
bel claim, which suggested non-interference of formula-
tion excipients in the estimation. 
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IZVOD 
KVANTITATIVNO ODREĐIVANJE TRIMAZOLIN HIDROHLORIDA U FARMACEUTSKIM PREPARATIMA 
PRIMENOM RP-HPLC METODE 
Ivana M. Savić
1,Goran S. Nikolić
1, Vladimir M. Banković
2, Ivan M. Savić
1 
1Tehnološki fakultet, Bulevar oslobodjenja 124, Leskovac 
2Farmaceutska i hemijska industrija, Zdravlje-Actavis, Vlajkova 199, Leskovac 
(Naučni rad) 
Selektivna i specifična RP-HPLC metoda razvijena je i potvrđena za kvan-
titativno određivanje trimazolin hidrohlorida u nazalnim preparatima. Mo-
bilna faza sastoji se od vode i acetonitrila (50:50 v/v), a UV detekcija je 
vršena na 270 nm. Linerni opseg važio je u oblasti koncetracija od 10 do
110 μg cm
-3. Metoda je testirana i potvrđena za različite analitičke para-
metre prema ICH upustvu. Vrednosti granice dokazivanja i kvantifikacije
iznosile su 1,45, odnosno 4,8 μg cm
-3. Rezultati eksperimenta pokazali su
da je predložena metoda precizna, tačna i reproduktivna za određivanje tri-
mazolin-hidrohlorida u nazalnim preparatima. 
  Ključne reči: Trimazolin-hidrohlorid
 HPLC  Validacija 
Key words: Trimazolin hydrochloride
 HPLC  Validation 
 